Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 in colorectal cancer: from a master player to a privileged therapy target.

Journal of translational medicine - 19 Jun 2025

Yan Sicheng, Zhan Fuyuan, He Yuxuan, Zhu Yuehong, Ma Zhihong

Abstract excerpt

Colorectal cancer (CRC) is the third most prevalent malignancy and the second leading cause of cancer-related mortality worldwide. The pathogenesis of CRC primarily stems from the gradual accumulation of genetic mutations, which drive oncogene (e.g., KRAS) activation and tumor suppressor gene (e.g., TP53) inactivation. Loss of genetic stability facilitates the conversion of proto-oncogenes into active oncogenes...

Topics

Join the communities discussing this publication.

Cancer-related Molecular Pathways
Cancer Research and Treatments
Colorectal Neoplasms
KRAS gene
TP53 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Molecular Targeted Therapy

Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 40537809
DOI: 10.1186/s12967-025-06566-4
PMCID: PMC12178040

Genes

TP53
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 in colorectal cancer: from a master player to a privileged therapy target.PMID 40537809Read ↗

Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors.Semantic proximity Read ↗

P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.Semantic proximity Read ↗

The Role of p53 Signaling in Colorectal CancerSemantic proximity Read ↗

Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant.Semantic proximity Read ↗

Mutant p53 in cancer therapy—the barrier or the pathSemantic proximity Read ↗

Mutant p53 in Cancer Progression and Targeted TherapiesSemantic proximity Read ↗

Gain-of-function mutant p53 in cancer progression and therapySemantic proximity Read ↗

An updated review of a novel method for examining P53 mutations in different forms of cancer.Semantic proximity Read ↗

Mutant p53 in colon cancerSemantic proximity Read ↗

Drugs Targeting p53 Mutations with FDA Approval and in Clinical TrialsSemantic proximity Read ↗

Tumor suppressor p53 and its gain-of-function mutants in cancer.Semantic proximity Read ↗

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and OpportunitiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.